Cargando…

Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites

OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) is an increasing healthcare burden worldwide. We examined the role of dietary cholesterol in driving NAFLD–HCC through modulating gut microbiota and its metabolites. DESIGN: High-fat/high-cholesterol (HFHC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiang, Coker, Olabisi Oluwabukola, Chu, Eagle SH, Fu, Kaili, Lau, Harry C H, Wang, Yi-Xiang, Chan, Anthony W H, Wei, Hong, Yang, Xiaoyong, Sung, Joseph J Y, Yu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948195/ https://www.ncbi.nlm.nih.gov/pubmed/32694178 http://dx.doi.org/10.1136/gutjnl-2019-319664

Ejemplares similares

Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review
por: Kenneally, Susan, et al.
Publicado: (2017)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia
por: Chihota, Belinda Varaidzo, et al.
Publicado: (2022)

Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome
por: Asfari, Mohammad Maysara, et al.
Publicado: (2020)

Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
por: Wood, Kayleigh L, et al.
Publicado: (2015)

Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway
por: Li, Meng, et al.
Publicado: (2018)

Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort
por: Olubamwo, Olubunmi O, et al.
Publicado: (2019)

Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease
por: Naimimohasses, Sara, et al.
Publicado: (2022)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
por: Sayiner, Mehmet, et al.
Publicado: (2016)

High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study
por: Duseja, Ajay, et al.
Publicado: (2019)

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
por: Montagner, Alexandra, et al.
Publicado: (2016)

Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease
por: Mehta, Rohini, et al.
Publicado: (2016)

Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury
por: Arriazu, Elena, et al.
Publicado: (2017)

Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans
por: Che, Li, et al.
Publicado: (2020)

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
por: Maev, Igor V, et al.
Publicado: (2020)

Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study
por: Tincopa, Monica A, et al.
Publicado: (2021)

Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya
por: Mburu, Anne Njeri, et al.
Publicado: (2023)

Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia
por: Rahman, M Masudur, et al.
Publicado: (2020)

Dysregulated activation of fetal liver programme in acute liver failure
por: Hyun, Jeongeun, et al.
Publicado: (2019)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
por: Afonso, Marta B, et al.
Publicado: (2021)

Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study
por: Coelho, Juliana Moraes, et al.
Publicado: (2020)

Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells
por: Dai, Zhen, et al.
Publicado: (2020)

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
por: Scragg, Jadine, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease burden: Australia, 2019–2030
por: Adams, Leon A, et al.
Publicado: (2020)

Mechanisms of liver disease in patients infected with HIV
por: Kaspar, Matthew B, et al.
Publicado: (2017)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Changing trends of hospitalisation of liver cirrhosis in Beijing, China
por: Bao, Xiao-Yuan, et al.
Publicado: (2015)

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016)

Loss of hepatic Mboat7 leads to liver fibrosis
por: Thangapandi, Veera Raghavan, et al.
Publicado: (2021)

STAT4-associated natural killer cell tolerance following liver transplantation
por: Jamil, K M, et al.
Publicado: (2017)

MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway
por: Wu, Heng, et al.
Publicado: (2016)

Does COVID-19 infection significantly affect liver transplantation? Results of liver transplantation in the COVID-19 era at a single, high-volume centre
por: Moradi, Alimohammad, et al.
Publicado: (2023)

COVID-19 and liver cancer: lost patients and larger tumours
por: Geh, Daniel, et al.
Publicado: (2022)

Effect of COVID-19 on presentations of decompensated liver disease in Scotland
por: Manship, Thomas, et al.
Publicado: (2022)

Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis
por: Salhab, Ahmad, et al.
Publicado: (2022)

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
por: Scarzello, Anthony J, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ujo575p5k2vfsjjj8t783cgh7j